These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21418385)

  • 21. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.
    Mruthinti S; Buccafusco JJ; Hill WD; Waller JL; Jackson TW; Zamrini EY; Schade RF
    Neurobiol Aging; 2004 Sep; 25(8):1023-32. PubMed ID: 15212827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid clearance as a treatment target against Alzheimer's disease.
    Kurz A; Perneczky R
    J Alzheimers Dis; 2011; 24 Suppl 2():61-73. PubMed ID: 21422524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
    Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
    Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aβ(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins.
    Wan W; Cao L; Liu L; Zhang C; Kalionis B; Tai X; Li Y; Xia S
    J Neurochem; 2015 Jul; 134(2):382-93. PubMed ID: 25866188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.
    Niewoehner J; Bohrmann B; Collin L; Urich E; Sade H; Maier P; Rueger P; Stracke JO; Lau W; Tissot AC; Loetscher H; Ghosh A; Freskgård PO
    Neuron; 2014 Jan; 81(1):49-60. PubMed ID: 24411731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic cerebral hypoperfusion-induced impairment of Aβ clearance requires HB-EGF-dependent sequential activation of HIF1α and MMP9.
    Ashok A; Rai NK; Raza W; Pandey R; Bandyopadhyay S
    Neurobiol Dis; 2016 Nov; 95():179-93. PubMed ID: 27431094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier.
    Pflanzner T; Petsch B; André-Dohmen B; Müller-Schiffmann A; Tschickardt S; Weggen S; Stitz L; Korth C; Pietrzik CU
    J Cereb Blood Flow Metab; 2012 Apr; 32(4):628-32. PubMed ID: 22293988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease.
    Kojro E; Postina R
    J Alzheimers Dis; 2009; 16(4):865-78. PubMed ID: 19387119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier.
    Merino-Zamorano C; Fernández-de Retana S; Montañola A; Batlle A; Saint-Pol J; Mysiorek C; Gosselet F; Montaner J; Hernández-Guillamon M
    J Alzheimers Dis; 2016 May; 53(2):677-91. PubMed ID: 27232214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.
    Deane R; Sagare A; Hamm K; Parisi M; LaRue B; Guo H; Wu Z; Holtzman DM; Zlokovic BV
    J Neurosci; 2005 Dec; 25(50):11495-503. PubMed ID: 16354907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
    Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
    Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.
    Vodopivec I; Galichet A; Knobloch M; Bierhaus A; Heizmann CW; Nitsch RM
    Neurodegener Dis; 2009; 6(5-6):270-80. PubMed ID: 20145420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
    Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
    Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the shortest Aβ-peptide generating highly specific antibodies against the C-terminal end of amyloid-β42.
    Axelsen TV; Holm A; Christiansen G; Birkelund S
    Vaccine; 2011 Apr; 29(17):3260-9. PubMed ID: 21371581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro investigation of amyloid-β hepatobiliary disposition in sandwich-cultured primary rat hepatocytes.
    Mohamed LA; Kaddoumi A
    Drug Metab Dispos; 2013 Oct; 41(10):1787-96. PubMed ID: 23852717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
    Donahue JE; Johanson CE
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes.
    Candela P; Saint-Pol J; Kuntz M; Boucau MC; Lamartiniere Y; Gosselet F; Fenart L
    Brain Res; 2015 Jan; 1594():15-26. PubMed ID: 25451130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model.
    Balazs Z; Panzenboeck U; Hammer A; Sovic A; Quehenberger O; Malle E; Sattler W
    J Neurochem; 2004 May; 89(4):939-50. PubMed ID: 15140193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.